To: Healthcare Providers, Hospitals, Local Health Departments, Sexual Health Providers, Family Planning Providers, Emergency Rooms, Community Health Centers, College Health Centers, and Internal Medicine, Family Medicine, Pediatric, Adolescent Medicine, Infectious Disease, Primary Care Providers, Higher Education Institution Health Clinics, Urgent Care providers, Community Based Organizations, County Jails, Emergency Rooms, Substance Use Disorder Treatment Facilities, Local Health Departments, and Planned Parenthoods.

From: New York State Department of Health, AIDS Institute

Date: October 9, 2026

UPDATE: The Food and Drug Administration (FDA) has announced extensions of some expiration dates of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension).

Dear Clinicians:

This is an update to earlier health advisories on August 1,2025 and March 10,2026 related to the recall and shortage of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension). We have just received news that the Food and Drug Association (FDA) has extended the expiration dates on certain batches of the medication. Bicillin® L-A (Penicillin G Benzathine Injectable Suspension) remains the only known effective antimicrobial for treating fetal infection and preventing congenital syphilis.

The following Bicillin L-A lot numbers are now permitted for extended use (use beyond their current labeled expiration date):

Product	Company	NDC Number	Lot Number	Expiration Date (Labeled)	Extended Use Date
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2955	28-Feb-2026	28-Feb-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2957	30-Apr-2026	30-Apr-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2956	30-Apr-2026	30-Apr-2027

Product	Company	NDC Number	Lot Number	Expiration Date (Labeled)	Extended Use Date
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2961	30-Jun-2026	30-Jun-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2958	30-Jun-2026	30-Jun-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	FT9676	30-Sep-2025	30-Sep-2026
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2959	31-Aug-2026	31-Aug-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GL2960	31-Aug-2026	31-Aug-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GT2489	31-Mar-2026	31-Mar-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	FC3938	31-Oct-2025	31-Oct-2026
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GT2603	31-Oct-2026	31-Oct-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GT2600	31-Oct-2026	31-Oct-2027

Product	Company	NDC Number	Lot Number	Expiration Date (Labeled)	Extended Use Date
Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units/2 mL	Pfizer, Inc.	60793-701-10	GT2602	31-Oct-2026	31-Oct-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2604	30-Nov-2026	30-Jun-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2606	30-Nov-2026	30-Jun-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	HE3990	30-Nov-2026	30-Jun-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2598	30-Sep-2026	30-Apr-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2599	30-Sep-2026	30-Apr-2027
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2608	31-Mar-2026	31-Oct-2026
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2450	31-May-2026	31-Dec-2026
Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units/4 mL	Pfizer, Inc.	60793-702-10	GT2582	31-May-2026	31-Dec-2026

Additional information on drug shortages can be found here: https://www.fda.gov/drugs/drug-shortages/search-list-extended-use-dates-assist-drug-shortages

Lentocilin® (Benzathine Benzylpenicillin Tetrahydrate) powder and diluent for suspension for injection remains an alternative for non-pregnant persons if the Bicillin L-A remains unavailable. https://www.cdc.gov/sti/hcp/clinical-guidance/availability-of-products.html

We also encourage providers to consider employing Doxycycline Post-exposure Prophylaxis (DoxyPEP) as appropriate to reduce incidence of new syphilis infections in individuals who are at higher risk of acquiring sexually transmitted infections

##################################

Sincerely,

Charles John Gonzalez, MD
Medical Director, AIDS Institute
New York State Department of Health

Rachel Hart-Malloy, PhD MPH
Director, Office of Sexual Health and Epidemiology
AIDS Institute
New York State Department of Health